The role of neurolytic celiac plexus block in the treatment of pancreatic cancer pain.
Pancreatic carcinoma, an important leading cause of cancer death, has increased steadily in incidence and still has a poor prognosis. Pain is one of the most frequent symptoms, affecting more than 75% of patients. It is often present in the early stages of disease and may be severe and difficult to treat. Abdominal viscera, including pancreas, liver, gallbladder, adrenal, kidney, and the gastrointestinal tract from the level of the gastroesophageal junction to the splenic flexure of the colon are innervated, at least in part, via the celiac plexus. Thus, painful tumors in these viscera may have pain relieved through the use of a neurolytic celiac plexus block (NCPB). Although some investigators questioned the role and the efficacy of NCPB in the treatment of upper abdominal cancer pain, most of them have suggested that it may represent the optimal treatment, especially for pancreatic cancer pain. In this report we have reviewed the techniques, results, and complications of NCPB for the treatment of pancreatic cancer pain.
Polati
E
E
Anestesia e Rianimazione A, Ospedale Civile Maggiore (VR), Azienda Ospedaliero-Universitaria di Verona, Verona, Italy. enpolati@tin.it
Luzzani
A
A
Schweiger
V
V
Finco
G
G
Ischia
S
S
D000779:Anesthetics, Local / Q000008:administration & dosage / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D001340:Autonomic Nerve Block / Q000379:methods*; D002045:Bupivacaine / Q000008:administration & dosage / Q000627:therapeutic use; D002447:Celiac Plexus; D006801:Humans; D010148:Intractable Pain / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000503:physiopathology*; D011292:Premedication
D000779:Anesthetics, Local; D001285:Atropine; D002045:Bupivacaine